+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Meningococcal Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026

  • ID: 4851385
  • Report
  • April 2019
  • Region: Global
  • 189 pages
  • Transparency Market Research
1 of 2

Global Meningococcal Vaccines Market: Overview

This report analyzes the current and future scenario of the global meningococcal vaccines market. Advancements in healthcare, increase in awareness and education through various non-profit organizations, and a rise in patient awareness and health care expenditure are key factors that are projected to drive the global market during the forecast period. 

The global meningococcal vaccines market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on type, end-user, and region. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the overview section. Additionally, the section comprises a competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global meningococcal vaccines market. 

Global Meningococcal vaccines Market: Key Segments

The global meningococcal vaccines market has been segmented based on type, end-user, and region. In terms of type, the global market has been classified into polysaccharide vaccines, conjugate vaccines, combination vaccines, and Men B vaccines. The polysaccharide vaccines segment has been further sub-segmented into Menomune, Mencevax, NmVac4, and others. The conjugate vaccines segment has been further sub-segmented into Menactra, Menveo, NeisVac-C, Nimenrix, Meningitec, Menjugate, MenAfriVac, and NmVac4-DT. The combination vaccines segment has been further split into MenHibrix, and Menitorix. The Men B vaccines segment has been further sub-segmented into Bexsero, and Trumenba. Based on end-user, the market has been classified into retail pharmacies, hospital pharmacies, and others. Based on region, the global market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these segments have been provided for the period from 2017 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. 

Global Meningococcal vaccines Market: Regional Outlook

In terms of region, the global meningococcal vaccines market has been segmented into North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, Israel, and rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries/sub-regions have been provided for the period from 2017 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions. 

Companies Mentioned in the Report

The report also profiles major players in the global meningococcal vaccines market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The major players profiled in the market report include Sanofi SA, Novartis International, GlaxoSmithKline plc, Pfizer Inc., Nuron Biotech, JN-International Medical Corporation, Serum Institute of India Ltd., Baxter International, and Biomed Pvt. Ltd. 

Note: Product cover images may vary from those shown
2 of 2
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Meningococcal Vaccines Market

4. Market Overview
4.1. Introduction
4.1.1. Type Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.3.4. Market Trends
4.4. Global Meningococcal Vaccines Market Analysis and Forecast, 2016-2026
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis

5. Market Outlook
5.1.Pipeline Analysis
5.2. Epidemiology Of Meningococcal Disease
5.3. Regulatory Scenario.

6. Global Meningococcal Vaccines Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Global Meningococcal Vaccines Market Value Forecast, by Type, 2016-2026
6.3.1. Polysaccharide
6.3.1.1. Menomune
6.3.1.2. Mencevax
6.3.1.3. NmVac4
6.3.1.4. Others
6.3.2. Conjugate Vaccines
6.3.2.1. Menactra
6.3.2.2. Menveo
6.3.2.3. NeisVac-C
6.3.2.4. Nimenrix
6.3.2.5. Meningitec
6.3.2.6. Menjugate
6.3.2.7. MenAfriVac
6.3.2.8. NmVac4-DT
6.3.3. Combination Vaccines
6.3.3.1. MenHibrix
6.3.3.2. Menitorix
6.3.4. Men B Vaccines
6.3.4.1. Bexsero
6.3.4.2. Trumenba
6.3.5. Others

7. Global Meningococcal Vaccines Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Global Meningococcal Vaccines Market Value Forecast, by End-user, 2016-2026
7.3.1. Retail Pharmacies
7.3.2. Hospital Pharmacies
7.3.3. Others
7.4. Global Meningococcal Vaccines Market Attractiveness, by End-user

8. Global Meningococcal Vaccines Market Analysis and Forecast, by Region/Sub-Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia-Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Global Meningococcal Vaccines Market Attractiveness, by Region/Sub-Region

9. North America Meningococcal Vaccines Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.1.1. Key Findings
9.2. North America Meningococcal Vaccines Market Value Forecast, by Type, 2016-2026
9.2.1. Polysaccharide
9.2.1.1. Menomune
9.2.1.2. Mencevax
9.2.1.3. NmVac4
9.2.1.4. Others
9.2.2. Conjugate Vaccines
9.2.2.1. Menactra
9.2.2.2. Menveo
9.2.2.3. NeisVac-C
9.2.2.4. Nimenrix
9.2.2.5. Meningitec
9.2.2.6. Menjugate
9.2.2.7. MenAfriVac
9.2.2.8. NmVac4-DT
9.2.3. Combination Vaccines
9.2.3.1. MenHibrix
9.2.3.2. Menitorix
9.2.4. Men B Vaccines
9.2.4.1. Bexsero
9.2.4.2. Trumenba
9.2.5. Others
9.3. North America Meningococcal Vaccines Market Value Forecast, by End-user, 2016-2026
9.3.1. Retail Pharmacies
9.3.2. Hospital Pharmacies
9.3.3. Others
9.4. North America Meningococcal Vaccines Market Value Forecast, by Country, 2016-2026
9.4.1. U.S.
9.4.2. Canada
9.5. North America Meningococcal Vaccines Market Attractiveness Analysis
9.5.1. By Type
9.5.2. By End-user
9.5.3. By Country

10. Europe Meningococcal Vaccines Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Europe Meningococcal Vaccines Market Value Forecast, by Type, 2016-2026
10.2.1. Polysaccharide
10.2.1.1. Menomune
10.2.1.2. Mencevax
10.2.1.3. NmVac4
10.2.1.4. Others
10.2.2. Conjugate Vaccines
10.2.2.1. Menactra
10.2.2.2. Menveo
10.2.2.3. NeisVac-C
10.2.2.4. Nimenrix
10.2.2.5. Meningitec
10.2.2.6. Menjugate
10.2.2.7. MenAfriVac
10.2.2.8. NmVac4-DT
10.2.3. Combination Vaccines
10.2.3.1. MenHibrix
10.2.3.2. Menitorix
10.2.4. Men B Vaccines
10.2.4.1. Bexsero
10.2.4.2. Trumenba
10.2.5. Others
10.3. Europe Meningococcal Vaccines Market Value Forecast, by End-user, 2016-2026
10.3.1. Retail Pharmacies
10.3.2. Hospital Pharmacies
10.3.3. Others
10.4. Europe Meningococcal Vaccines Market Value Forecast, by Country/Sub-Region, 2016-2026
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Europe Meningococcal Vaccines Market Attractiveness Analysis
10.5.1. By Type
10.5.2. By End-user
10.5.3. By Country/Sub-Region

11. Asia-Pacific Meningococcal Vaccines Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Asia Pacific Meningococcal Vaccines Market Value Forecast, by Type, 2016-2026
11.2.1. Polysaccharide
11.2.1.1. Menomune
11.2.1.2. Mencevax
11.2.1.3. NmVac4
11.2.1.4. Others
11.2.2. Conjugate Vaccines
11.2.2.1. Menactra
11.2.2.2. Menveo
11.2.2.3. NeisVac-C
11.2.2.4. Nimenrix
11.2.2.5. Meningitec
11.2.2.6. Menjugate
11.2.2.7. MenAfriVac
11.2.2.8. NmVac4-DT
11.2.3. Combination Vaccines
11.2.3.1. MenHibrix
11.2.3.2. Menitorix
11.2.4. Men B Vaccines
11.2.4.1. Bexsero
11.2.4.2. Trumenba
11.2.5. Others
11.3. Asia Pacific Meningococcal Vaccines Market Value Forecast, by End-user, 2016-2026
11.3.1. Retail Pharmacies
11.3.2. Hospital Pharmacies
11.3.3. Others
11.4. Asia Pacific Meningococcal Vaccines Market Value Forecast, by Country/Sub-Region, 2016-2026
11.4.1. Japan
11.4.2. China
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia-Pacific
11.5. Asia Pacific Meningococcal Vaccines Market Attractiveness Analysis
11.5.1. By Type
11.5.2. By End-user
11.5.3. By Country/Sub-Region

12. Latin America Meningococcal Vaccines Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Latin America Meningococcal Vaccines Market Value Forecast, by Type, 2016-2026
12.2.1. Polysaccharide
12.2.1.1. Menomune
12.2.1.2. Mencevax
12.2.1.3. NmVac4
12.2.1.4. Others
12.2.2. Conjugate Vaccines
12.2.2.1. Menactra
12.2.2.2. Menveo
12.2.2.3. NeisVac-C
12.2.2.4. Nimenrix
12.2.2.5. Meningitec
12.2.2.6. Menjugate
12.2.2.7. MenAfriVac
12.2.2.8. NmVac4-DT
12.2.3. Combination Vaccines
12.2.3.1. MenHibrix
12.2.3.2. Menitorix
12.2.4. Men B Vaccines
12.2.4.1. Bexsero
12.2.4.2. Trumenba
12.2.5. Others
12.3. Latin America Meningococcal Vaccines Market Value Forecast, by End-user, 2016-2026
12.3.1. Retail Pharmacies
12.3.2. Hospital Pharmacies
12.3.3. Others
12.4. Latin America Meningococcal Vaccines Market Value Forecast, by Country/Sub-Region, 2016-2026
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Type
12.5.2. By End-user
12.5.3. By Country/Sub-Region

13. Middle East & Africa Meningococcal Vaccines Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by Type, 2016-2026
13.2.1. Polysaccharide
13.2.1.1. Menomune
13.2.1.2. Mencevax
13.2.1.3. NmVac4
13.2.1.4. Others
13.2.2. Conjugate Vaccines
13.2.2.1. Menactra
13.2.2.2. Menveo
13.2.2.3. NeisVac-C
13.2.2.4. Nimenrix
13.2.2.5. Meningitec
13.2.2.6. Menjugate
13.2.2.7. MenAfriVac
13.2.2.8. NmVac4-DT
13.2.3. Combination Vaccines
13.2.3.1. MenHibrix
13.2.3.2. Menitorix
13.2.4. Men B Vaccines
13.2.4.1. Bexsero
13.2.4.2. Trumenba
13.2.5. Others
13.3. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by End-user, 2016-2026
13.3.1. Retail Pharmacies
13.3.2. Hospital Pharmacies
13.3.3. Others
13.4. Middle East & Africa Meningococcal Vaccines Market Value Forecast, by Country/Sub-Region, 2016-2026
13.4.1. GCC Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of Middle East & Africa
13.5. Middle East & Africa Meningococcal Vaccines Market Attractiveness Analysis
13.5.1. By Type
13.5.2. By End-user
13.5.3. By Country/Sub-Region

14. Competition Landscape
14.1. Market Player - Competition Matrix (By Tier and Size of companies)
14.2. Competitive Business Strategies
14.3. Company Profiles
14.3.1. Neuron Biotech
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Financial Overview
14.3.1.3. Product Portfolio
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Baxter international
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Financial Overview
14.3.2.3. Product Portfolio
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Pfizer Inc.
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Financial Overview
14.3.3.3. Product Portfolio
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Novartis International
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Financial Overview
14.3.4.3. Product Portfolio
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Sanofi S.A
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Financial Overview
14.3.5.3. Product Portfolio
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. JN-International Medical Corporation
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Financial Overview
14.3.6.3. Product Portfolio
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Biomed Pvt. Ltd.
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Financial Overview
14.3.7.3. Product Portfolio
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Serum Institute of India Ltd
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Financial Overview
14.3.8.3. Product Portfolio
14.3.8.4. SWOT Analysis
14.3.8.5. Strategic Overview
14.3.9. GlaxoSmithKline plc
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Financial Overview
14.3.9.3. Product Portfolio
14.3.9.4. SWOT Analysis
14.3.9.5. Strategic Overview
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll